ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6009-Nedlands-One-Clinical-Research
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
20
trial(s) found.
NCT07221474
Advanced
Phase 2
Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013) (
INTerpath-13
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Squamous non-small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6009 - Nedlands - One Clinical Research
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
Itraconazole
Pumitamig
SMO inhibitor
bispecific PD-L1/VEGFA antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,SMO-targeting
cancer therapy,VEGFA-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGFA-targeting
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06961006
Advanced
Phase 2
Recruiting
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012) (
V940-012
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06868199
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (
LM168-01-101
)
anti-PD-1 monoclonal antibody
unknown drug class
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
WA
6009 - Nedlands - One Clinical Research
NCT06820463
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer (
AndroMETa-CRC
)
anti-cMET antibody-drug conjugate
Colorectal cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06819735
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (
DOMISOL
, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06650566
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (
LM299-01-102
)
bispecific PD-1/VEGF antibody
Cancer
WA
6009 - Nedlands - One Clinical Research
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06596473
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors (
BG-C477-101
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06384352
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (
YL211-INT-101-01
)
anti-cMET antibody-drug conjugate
Solid tumour
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT06345729
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004) (
1084-004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06112314
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (
PRISM-MEL-301
anti-PD-1 monoclonal antibody
bispecific T-cell engager,PRAME-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
NCT06077760
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (
INTerpath-002
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT05607498
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (
EMB07X101
)
bispecific T-cell engager,ROR1-targeting
Lymphoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05533697
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (
mRNA-4359-P101
)
mRNA personalised cancer vaccine,IDO/PD-L1-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2228 - Miranda - Southside Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05315700
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (
ORIC-114-01
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05205109
Advanced
Phase 1
Recruiting
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
ATG-037-001
)
CD73 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit (TERMINATED)
WA
6009 - Nedlands - One Clinical Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
NOT Breast cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (20)
Recruitment Country and State
WA (20)
NSW (17)
VIC (16)
QLD (8)
SA (5)
NZ (5)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (9)
Phase 2 (3)
Phase 3 (4)
Trial Type
Advanced (18)
Curative (2)
Cancer Therapy Class
PD-1/PD-L1
75%
PD-1
70%
PD-L1
10%
EGFR
10%
MET
10%
VEGF
10%
CCR8
10%
SMO
5%
VEGFA
5%
CEACAM5
5%
Trop2
5%
KRAS
5%
KRAS G12C
5%
LAG3
5%
PRAME
5%
ROR1
5%
CTLA4
5%
IDO
5%
ERBB2
5%
CD73
5%
TP53
5%
TP53 Y220C
5%
Facility
6009 - Nedlands - One Clinical Research (20)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
4215 - Southport - Tasman Oncology (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3168 - Clayton - Monash Medical Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2500 - Wollongong - Cancer Care Wollongong (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2170 - Liverpool - Liverpool Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Melanoma
Breast cancer
Gynaecological cancer
Upper gastrointestinal cancer
Cervical cancer
Colorectal adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
HPV-related cancer
HPV16-positive cancer
Oesophageal cancer
Viral-related cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Breast adenocarcinoma
Head and neck cancer
Ovarian cancer
Triple-negative breast cancer
Urogenital cancer
Squamous non-small-cell lung cancer
Mucosal melanoma
Uveal melanoma
Biliary tract cancer
Hepatobiliary cancer
Haematological malignancy
Lymphoma
Clear cell renal cell carcinoma
Head and neck squamous cell carcinoma
Kidney cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Urothelial carcinoma
Bladder cancer
Carcinoma
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Male genital cancers
Neuroendocrine carcinoma
Prostate cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy